Adam D. Levy - 14 Jan 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: Chief Financial Officer
Signature: /s/ Adam D. Levy
Issuer symbol: ACRV
Transactions as of: 14 Jan 2026
Net transactions value: +$14,999
Form type: 4
Filing time: 16 Jan 2026, 16:01:38 UTC
Previous filing: 05 Aug 2025
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Levy Adam D.	Chief Financial Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN	/s/ Adam D. Levy	16 Jan 2026	0002061876

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Purchase	$14,999	+8,832	+73%	$1.70	20,983	14 Jan 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.

Content

The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.